{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:37:13Z","timestamp":1789875433537,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T00:00:00Z","timestamp":1510963200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct comparisons of the effectiveness of allopurinol with that of other urate-lowering agents in chronic kidney disease (CKD) populations, as well as guideline recommendations for clinical practice, are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We constructed a pharmacoepidemiology cohort study by including patients from Taiwan\u2019s long-term integrated CKD care program to compare the effectiveness among allopurinol, febuxostat and benzbromarone in reducing the risk of progression to dialysis. A total of 874 patients with hyperuricemia who were newly treated with allopurinol, febuxostat or benzbromarone were included. The primary and secondary outcomes were incident end-stage renal disease (ESRD) and the serum uric acid (SUA) changes from baseline, respectively. The results were analyzed using multiple Cox proportional models adjusted for multinomial propensity scores. For subgroup analyses, we further stratified patients according to whether their latest SUA level reached the therapeutic target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with allopurinol, benzbromarone therapy was associated with a reduced risk of progression to dialysis, the adjusted hazard ratio was 0.50 (95% confidence interval, 0.25\u20130.99). Patients who received allopurinol or febuxostat exhibited a comparable risk of ESRD [adjusted hazard ratio, 0.99 (0.40\u20132.44)]. Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model. Among patients who reached the therapeutic target, those with febuxostat and benzbromarone initiation had a significantly lower risk of ESRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, compared with conventional allopurinol, febuxostat and benzbromarone may be more effective in reducing the risk of progression to dialysis and in lowering SUA levels in CKD populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfx313","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T15:22:18Z","timestamp":1507821738000},"page":"1620-1627","source":"Crossref","is-referenced-by-count":43,"title":["Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-5905","authenticated-orcid":false,"given":"Hsu-Wen","family":"Chou","sequence":"first","affiliation":[{"name":"Clinical Research Outcome and Training Center, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Tsai","family":"Chiu","sequence":"additional","affiliation":[{"name":"Clinical Research Outcome and Training Center, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wei","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kidney Institute and Division of Nephrology, China Medical University Hospital and College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Big Data Center, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen","family":"Ting","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kidney Institute and Division of Nephrology, China Medical University Hospital and College of Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chieh","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kidney Institute and Division of Nephrology, China Medical University Hospital and College of Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chun","family":"Huang","sequence":"additional","affiliation":[{"name":"Clinical Research Outcome and Training Center, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chi","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kidney Institute and Division of Nephrology, China Medical University Hospital and College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Big Data Center, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CMUH Kidney Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"2025102312504348900_gfx313-B1","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2025102312504348900_gfx313-B2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ndt\/gft378","article-title":"Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis","volume":"29","author":"Bose","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312504348900_gfx313-B3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","article-title":"Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis","volume":"16","author":"Kanji","year":"2015","journal-title":"BMC Nephrol"},{"key":"2025102312504348900_gfx313-B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2025102312504348900_gfx313-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18400","article-title":"Allopurinol for the treatment of chronic kidney disease: a systematic review","volume":"18","author":"Fleeman","year":"2014","journal-title":"Health Technol Assess"},{"key":"2025102312504348900_gfx313-B6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2025102312504348900_gfx313-B7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025102312504348900_gfx313-B8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11926-010-0093-2","article-title":"New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond","volume":"12","author":"Schlesinger","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"2025102312504348900_gfx313-B9","first-page":"ii15","article-title":"Febuxostat: a new treatment for hyperuricaemia in gout","volume":"48 (Suppl 2)","author":"Edwards","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2025102312504348900_gfx313-B10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/hr.2014.107","article-title":"Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction","volume":"37","author":"Shibagaki","year":"2014","journal-title":"Hypertens Res"},{"key":"2025102312504348900_gfx313-B11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2025102312504348900_gfx313-B12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"2025102312504348900_gfx313-B13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/15257770.2011.622732","article-title":"Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease","volume":"30","author":"Fujimori","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2025102312504348900_gfx313-B14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jfma.2013.10.021","article-title":"Progression of stages 3b-5 chronic kidney disease\u2013preliminary results of Taiwan national pre-ESRD disease management program in Southern Taiwan","volume":"112","author":"Lin","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"2025102312504348900_gfx313-B15","first-page":"S1","article-title":". KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access","volume":"48 (Suppl 1)","author":"National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2025102312504348900_gfx313-B16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2215\/CJN.09810913","article-title":"Association of walking with survival and RRT among patients with CKD stages 3-5","volume":"9","author":"Chen","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312504348900_gfx313-B17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2025102312504348900_gfx313-B18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2025102312504348900_gfx313-B19","doi-asserted-by":"crossref","first-page":"e0170393","DOI":"10.1371\/journal.pone.0170393","article-title":"Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review","volume":"12","author":"Tsai","year":"2017","journal-title":"PLoS One"},{"key":"2025102312504348900_gfx313-B20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11596-014-1302-4","article-title":"Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis","volume":"34","author":"Zhang","year":"2014","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"2025102312504348900_gfx313-B21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumd00512-0083","article-title":"Allopurinol in patients with impaired renal function","volume":"25","author":"Levin","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"2025102312504348900_gfx313-B22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/annrheumd00512-0090","article-title":"Allopurinol therapy of gout with renal complications","volume":"25","author":"Sjoberg","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"2025102312504348900_gfx313-B23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.41.1.59","article-title":"Allopurinol treatment and its effect on renal function in gout: a controlled study","volume":"41","author":"Gibson","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"2025102312504348900_gfx313-B24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/08941939.2014.911395","article-title":"Allopurinol in renal ischemia","volume":"27","author":"Prieto-Moure","year":"2014","journal-title":"J Invest Surg"},{"key":"2025102312504348900_gfx313-B25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","article-title":"A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312504348900_gfx313-B26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/HYPERTENSIONAHA.116.08488","article-title":"Effect of uric acid-lowering agents on endothelial function: a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Borgi","year":"2017","journal-title":"Hypertension"},{"key":"2025102312504348900_gfx313-B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.b14-00514","article-title":"Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment","volume":"38","author":"Kadowaki","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"2025102312504348900_gfx313-B28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"2025102312504348900_gfx313-B29","first-page":"165","article-title":"Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective","volume":"21","author":"Gandhi","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"2025102312504348900_gfx313-B30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcme.2015.07.001","article-title":"Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia","volume":"8","author":"Nakagomi","year":"2015","journal-title":"IJC Metab Endocr"},{"key":"2025102312504348900_gfx313-B31","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/srep04554","article-title":"Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice","volume":"4","author":"Nomura","year":"2014","journal-title":"Sci Rep"},{"key":"2025102312504348900_gfx313-B32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/ki.2011.198","article-title":"Biomarkers in chronic kidney disease: a review","volume":"80","author":"Fassett","year":"2011","journal-title":"Kidney Int"},{"key":"2025102312504348900_gfx313-B33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1745-6215-15-26","article-title":"The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study","volume":"15","author":"Hosoya","year":"2014","journal-title":"Trials"},{"key":"2025102312504348900_gfx313-B34"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/33\/9\/1620\/25590876\/gfx313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/33\/9\/1620\/25590876\/gfx313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:59Z","timestamp":1761238319000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/33\/9\/1620\/4641623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,11,17]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfx313","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2017,11,17]]}}}